OKYO Pharma Limited (OKYO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

OKYO Pharma Limited (OKYO) closed at USD 1.41 on 2026-10-14, a change of -44.5 % over the past year, with a market capitalization of USD 75.05M.

OKYO Pharma Limited recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

OKYO Pharma Limited key figures

Previous close

USD 1.41 (2026-10-14)

1-year change

-44.5 %

Market cap

USD 75.05M

Enterprise value

USD 54.45M

P/E ratio (trailing)

-5.96

P/E ratio (forward)

-2.17

EPS (trailing)

-0.24

EPS (forward)

-0.66

PEG ratio

n/a

Price to book

6.09

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.42

Employees

5

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About OKYO Pharma Limited

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for OKYO Pharma Limited and compare it with other stocks.